We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
+8.23%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$236M
AUM Growth
-$42.2M
(-15%)
Cap. Flow
-$54M
Cap. Flow
% of AUM
-22.88%
Top 10 Holdings %
Top 10 Hldgs %
50.67%
Holding
47
New
9
Increased
8
Reduced
13
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$29.5M |
| 2 |
Abbott
ABT
|
+$6.58M |
| 3 |
Medtronic
MDT
|
+$5.05M |
| 4 |
Revvity
RVTY
|
+$4.7M |
| 5 |
Zimmer Biomet
ZBH
|
+$4.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$8.15M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$7.74M |
| 3 |
Biogen
BIIB
|
+$6.96M |
| 4 |
ResMed
RMD
|
+$5.74M |
| 5 |
Edwards Lifesciences
EW
|
+$5.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Smith & Nephew
SNN
$12.5B
| $4.36M | 1.85% |
140,000
-10,000
| -7% | -$297K |
|
|
27
Zimmer Biomet
ZBH
$18.7B
| $4.32M | 1.83% |
+40,000
| New | +$4.37M |
|
28
Repligen
RGEN
$9.35B
| $3.72M | 1.58% |
25,000
+10,000
| +67% | +$1.43M |
|
29
Maravai LifeSciences
MRVI
$861M
| $3.53M | 1.5% |
425,000
-25,000
| -6% | -$216K |
|
30
Humana
HUM
$46.7B
| $3.17M | 1.34% |
10,000
+2,500
| +33% | +$890K |
|
31
Teva Pharmaceuticals
TEVA
$42.8B
| $3.06M | 1.3% |
170,000
-30,000
| -15% | -$525K |
|
32
Stevanato
STVN
$5.8B
| $2.8M | 1.19% |
+140,000
| New | +$2.82M |
|
33
Ascendis Pharma A/S
ASND
$16.8B
| $1.49M | 0.63% |
+10,000
| New | +$1.35M |
|
34
Agilent Technologies
A
$41.9B
| – | – |
-35,000
| Closed | -$4.54M |
|
|
35
Biogen
BIIB
$30.9B
| – | – |
-30,000
| Closed | -$6.96M |
|
36
Bruker
BRKR
$9.03B
| – | – |
-40,000
| Closed | -$2.55M |
|
37
DexCom
DXCM
$34.3B
| – | – |
-30,000
| Closed | -$3.4M |
|
|
38
Edwards Lifesciences
EW
$53.6B
| – | – |
-60,000
| Closed | -$5.54M |
|
39
Medpace
MEDP
$16.7B
| – | – |
-7,500
| Closed | -$3.09M |
|
|
40
Merck
MRK
$328B
| – | – |
-65,874
| Closed | -$8.15M |
|
41
Natera
NTRA
$45.5B
| – | – |
-30,000
| Closed | -$3.25M |
|
42
Insulet
PODD
$10.1B
| – | – |
-25,000
| Closed | -$5.04M |
|
|
43
ResMed
RMD
$32.8B
| – | – |
-30,000
| Closed | -$5.74M |
|
|
44
Thermo Fisher Scientific
TMO
$223B
| – | – |
-14,000
| Closed | -$7.74M |
|
Similar funds
AFP
PCGDR
ACM
9C
STFP
ADEF
AC
CIP
Sivik Global Healthcare's Q3 2024 Portfolio in Review
As of Q3 2024, Sivik Global Healthcare held 47 positions worth $236M, down 15% from $278M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Sivik Global Healthcare withdrew a net $54M in Q3 2024, closing 12 positions and reducing 13 holdings. Its most notable exit was Merck, an estimated $8.15M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 80% a quarter earlier.
Against the trend, Sivik Global Healthcare opened a new position in State Street SPDR S&P Biotech ETF worth $29.6M.
- Sivik Global Healthcare's largest Q3 2024 buy was State Street SPDR S&P Biotech ETF: 300,000 shares worth $29.6M.
- Sivik Global Healthcare added most to Acadia Healthcare in Q3 2024, an estimated $2.53M increase.
- Sivik Global Healthcare's biggest Q3 2024 reduction was Vertex Pharmaceuticals, cutting an estimated $2.4M.
- Sivik Global Healthcare fully exited Merck in Q3 2024, selling an estimated $8.15M.
- Sivik Global Healthcare's ten largest holdings make up 51% of its $236M portfolio in Q3 2024.
- Sivik Global Healthcare opened 9 new positions and closed 12 in Q3 2024.
- Sivik Global Healthcare's portfolio value fell 15% quarter-over-quarter to $236M.
Based on Sivik Global Healthcare's 13F filing for Q3 2024, filed 6 Nov 2024.